Tidsskrift

Central hypothyroidism caused by roxadustat

Jostein Wågen Hauge, acting senior consultant and research fellow. The author has completed the ICMJE form and declares no conflicts of interest. Sadollah Abedini PhD, senior consultant. The author ...

DATROWAY® (datopotamab deruxtecan-dlnk) demonstrated unprecedented median overall survival improvement of five months vs. chemo as 1st-line treatment for patients with ...

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 60% and Risk of Death by 50% for Certain Patients …

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced landmark results demonstrating ...

IMFINZI® (durvalumab) regimen reduced the risk of disease recurrence or death by 32% in high-risk non-muscle-invasive bladder cancer in the POTOMAC Phase III trial

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.
Healthline

Hair Loss in Women

Female pattern baldness (androgenetic alopecia) is the most common cause of hair loss in women, but there are many other potential causes. Various treatment options are available depending on the ...
verywellhealth

What Is Secondary Hypothyroidism?

Secondary hypothyroidism happens when the pituitary gland does not make enough TSH to stimulate the thyroid, often due to a pituitary tumor. Symptoms include fatigue, dry skin, joint and muscle pain, ...